Photopheresis in Cutaneous T-Cell Lymphoma: Five-Year Experience

Abstract

Background

Cutaneous T-cell lymphoma (CTCL) includes several lymphoproliferative disorders involving mature T-lymphocyte proliferation initially confined to the cutis. These affections, after variable periods, may progress to the blood, limph nodes and visceral organs. Mycosis fungoides (MF) is the most frequent form of CTCL and has an indolent clinical course.

The therapy of CTCL depends on the stage of the disease and the patient's general conditions. For advanced cases it includes chemotherapy, retinoids, and interferon-α. Since 1987 extracorporeal photochemotherapy (ECP), a novel immunomodulatory approach based on apheresis and photo-irradiation of leukocytes, has been successfully introduced for the treatment of advanced CTCL. It can prolong survival of patients with erythrodermic CTCL without significant side effects. Objective: To review our five-year experience with ECP in CTCL.

Methods

Since June 1994, 33 CTCL patients have been recruited for ECP, using two different regimens: two procedures on two consecutive days at four-week intervals for six months, or at two-week intervals for three months with progressive tapering in the second three-month period for the more severe forms. Six patients received ECP with IFN-α. ECP was done using the photopheresis UVAR system and UVAR XTS (Therakos, West Chester, Pa) and always with 8-MOP liquid formulation injected directly into the buffy coat bag.

Lymphocytes in peripheral blood were immunophenotypically characterized for each patient and every ECP session.

Results

All patients tolerated ECP well, without significant side effects. Thirty patients are clinically evaluable (at least three ECP cycles). A favourable clinical response was obtained in 80.9% (16/21) of MF patients (complete response 33%, partial response 47.6%) and in 66% (6/9) of patients in the Sézary's syndrome phase (complete response 33.3%, partial response 33.3%). Five of the six patients given IFN-α as adjunctive therapy had a PR and one a CR. Four patients are in CR without therapy at follow-ups of 46, 20, 10 and 8 months. There have been no changes in the peripheral lymphocyte immunophenotype during the follow-up. In 19/30 patients the CD95 antigen, correlated with cellular apoptosis, was expressed and was frequently associated with a good clinical response. Conclusions: In our experience ECP achieved favourable clinical responses in 73% of patients, in monotherapy or in combination with IFN-α, without significant side effects. (Int J Artif Organs 2000; 23: 55–62)

Keywords

Cutaneous T-cell lymphoma Photopheresis IFN-α CD95 (Apo I/Fas)

Get full access to this article

View all access options for this article.

References

Edelson

R.L.

, Berger

C.L.

, Raafat

. Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin. J Invest Dermatol 1979; 73: 548–50.

Murphy

G.F.

. Cutaneous T cell lymphoma. Adv Pathol 1988; 1: 131–56.

Willemze

, Kerl

, Sterry

. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European organization for research and treatment of cancer. Blood 1997; 90: 354–71.

Springer

E.S.

, Kuzel

T.M.

, Rosen

S.T.

. International symposium on cutaneous T cell Lymphoma. J Am Acad Dermatol 1991; 24: 136–8.

Sézary

, Bouvrain

. Erythroderma avec presence de cellules monstrueses dans le derme el le sang circulant. Bull Soc Fr Dermatol Syphil 1938; 45: 357–68.

Willemze

, van Vloten

W.A.

, Hermans

. Diagnostic criteria in Sézary's syndrome. A multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. J Invest Dermatol 1983; 81: 392–7.

Gilchrest

B.A.

, Parrish

J.A.

, Tanenbaum

. Oral methoxoralen photochemotherapy of mycosis fungoides. Cancer 1976; 38: 683–9.

Vonderheid

E.C.

, Tan

E.T.

, Kantor

A.F.

. Long term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 416–28.

Zackheim

H.S.

, Epstein

E.H.

, Crain

W.R.

. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15 years experience in 143 patiens. J Am Acad Dermatol 1990; 22: 802–10.

10.

Bunn

P.A.

, Foon

K.A.

, Ihde

D.C.

. Recombinant leukocyte α-interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984; 101: 484–7.

11.

Thomsen

, Hammar

, Molin

. Retinoids plus PUVA (RePUVA) in mycosis fungoides plaque stage, Acta Derm Venerol (Stock) 1989; 69: 536–8.

12.

Hoppe

. The management of mycosis fungoides at Stanford University - standard and innovative treatment programs. Leukemia 1991; 5(s): 46–8.

13.

Mc Donald

, Bertino

. Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor. Cancer Treat Rep 1978; 62: 1009–14.

14.

Bierman

P.J.

, Vose

J.M.

, Armitage

J.O.

. Clinical manifestation and staging of and therapy for non Hodgkin's lymphomas. In: Hoffman

, Benz

E.J.

, Shattil

S.J.

, Furie

, Cohen

, Silberstein

L.E.

eds. Hematology. Basic principles and practice. Churchill-Livingstone II ed, 1995: 1278–98.

15.

Edelson

, Berger

, Gasparro

. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297–303.

16.

Lim

H.W.

, Edelson

. Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1117–26.

17.

Heald

, Rook

, Perez

. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427–33.

18.

Perez

, Edelson

, LaRoche

. Inhibition of antiskin allograft immunity by infusions with syngenic photoinactivated effector lymphocytes. J Invest Dermatol 1989; 92: 669–76.

19.

Song

P.S.

, Tapley

K.J.

. Photochemistry and photobiology of psoralens. Photochem Photobiol 1979; 29: 1177–97.

20.

Edelson

, Heald

, Perez

, Berger

. Extracorporeal Photochemotherapy. Biologic Therapy of Cancer 1994; 4: 1–12.

21.

Heald

P.W.

, Kim

H.Y.

, Perez

. T-cell responses in photoimmune therapy. J Clin Apheresis 1995; 10: 144–9.

22.

Vowels

, Cassin

, Boufal

. Extracorporeal photochemotherapy induces the production of tumor necrosis factor-α by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol 1992; 98: 686–92.

23.

Yoo

E.K.

, Rook

A.H.

, Elenitsas

. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996; 107: 235–42.

24.

Bunn

P.A.

, Lamberg

S.I.

. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 725–8.

25.

Bogen

S.A.

, Pelley

, Charif

. Immunophenotypic identification of Sézary cells in peripheral blood. Am J Clin Pathol 1996; 106: 739–48.

26.

Bernengo

M.G.

, Quaglino

, Novelli

. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical hematological and immunological features. Ann Oncol 1998; 9: 857–63.

27.

Knobler

R.M.

, Trautinger

, Graninger

. Parenteral administration of 8-methoxypsoralen in photopheresis. J Am Acad Dermatol 1993; 25: 580.

28.

Rook

A.H.

, Gottlieb

S.L.

, Wolfe

J.T.

. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 1997; 107(suppl): S16–20.

29.

Gottlieb

S.L.

, Wolfe

J.T.

, Fox

F.E.

. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alpha: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946–57.

30.

Duvic

, Hester

J.P.

, Lemak

N.A.

. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 573–9.

31.

Aringer

, Graninger

W.B.

, Smolen

J.S.

. Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. Br J Rheumatol 1997; 36: 1267.